Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLK-302 (Intratus)
- Development stage
- Unknown
- Lead developer
- Intratus
- Modality
- Small Molecules
- Administration
- Transdermal, Periocular
01
Overview
GLK-302 (Ilution) is an investigational transdermal/periocular drug delivery platform being developed by Intratus in partnership with Glaukos for the treatment of presbyopia. The platform utilizes a patented cream-based formulation applied to the outer surface of the eyelid, which acts as a depot for the transdermal delivery of pilocarpine to the eye. This approach provides a non-invasive, dropless alternative to traditional topical eye drops. Pilocarpine, the active pharmaceutical ingredient, is a small molecule muscarinic receptor agonist that induces miosis (pupillary constriction), thereby increasing the depth of focus and improving near vision in patients with presbyopia.
- Other names
- IlutionIlution GLK-302
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)
Beyond the preview
Go deeper on GLK-302 (Intratus).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLK-302 (Intratus).